Neoadjuvant immunotherapy in resectable non-small cell lung cancer

Area of Science:

• Oncology
• Immunology
• Thoracic Surgery

Background:

• Lung cancer remains a leading cause of cancer mortality globally, with limited survival rates even for operable cases.
• Cisplatin-based chemotherapy was the standard adjuvant treatment for resected non-small cell lung cancer (NSCLC).
• The advent of immunotherapy has significantly altered the therapeutic landscape for NSCLC.

Purpose of the Study:

• To review the biological basis for using immune checkpoint blockade in early-stage NSCLC.
• To summarize clinical trial data demonstrating advances in treating resectable NSCLC with immunotherapy.
• To highlight ongoing research and the importance of biomarkers in understanding treatment response.

Main Methods:

• Review of biological rationale for immune checkpoint blockade in NSCLC.
• Analysis of clinical trial data for neoadjuvant and adjuvant immunotherapy in resectable NSCLC.
• Summary of ongoing studies and biomarker research.

Main Results:

• Immune checkpoint blockade has led to significant improvements in clinical outcomes for early-stage NSCLC.
• New FDA approvals reflect the efficacy of immunotherapy in the neoadjuvant and adjuvant settings.
• Combination strategies involving immunotherapy, chemotherapy, and surgery are advancing treatment.

Conclusions:

• Immune checkpoint blockade represents a paradigm shift in managing early-stage resectable NSCLC.
• Ongoing trials and biomarker studies are crucial for optimizing treatment and understanding resistance mechanisms.
• Further research will refine the use of immunotherapy and identify predictive biomarkers for NSCLC patients.